Program
tisotumab vedotin
Also written as “Tisotumab Vedotin”, “TIVDAK” and “Tisotumab Vedotin (HuMax-TF-ADC)”.
Its studies are mostly in Uterine Cervical Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms · Neoplasm Metastasis, led by 3 companies.
Drug pageTisotumab vedotin: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 92 open or running | phase 4since Apr 15, 2025 | Nov 14, 2013 | Dec 13, 2028phase 4 · NCT06952660 |
| Genmab | 10 open or running | phase 2since Mar 29, 2019 | Mar 29, 2019 | none ahead |
| Zai Labits history only | 10 open or running | phase 1since Apr 27, 2023 | Apr 27, 2023 | none ahead |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Genmab only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named tisotumab vedotinINNProposed as its International Nonproprietary Name in WHO's List 113
- Mar 29, 2019First study: phase 2 study in Uterine Cervical NeoplasmsFirst studyNCT03913741 · 23 enrolled · Japan
TargetBeta
“An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, ”NCIt, by rule
“Coagulation factor III binding agent”ChEMBL 37, by rule
Other programs on F3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-TF/TOP1i Antibody-drug Conjugate XNW28012rule | Evopoint Biosciences | phase 3 | 3 |
| Anti-TF Antibody-drug Conjugate MRG004Arule | lepu-biopharma-co-ltd | phase 3 | 2 |
| SHR-4375 | Jiangsu HengRui Medicine | phase 2 | 2 |
| Anti-TF/TOP1i Antibody-drug Conjugate XB371rule | Exelixis | phase 1 | 1 |
| Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rule | sutro-biopharma-inc | phase 1 | 1 |
Studies
The one study Genmab leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03913741Uterine Cervical Neoplasms · Japan | 2 | Completed | Aug 14, 2020 | 23 |
How it is read
Names in the registry
- “tisotumab vedotin”, 5 entries
- “Tisotumab Vedotin”, 3 entries
- “TIVDAK”, 1 entry
- “Tisotumab Vedotin (HuMax-TF-ADC)”, 1 entry
- “Tisotumab vedotin (HuMax-TF-ADC)”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 5 studies
- Ovarian Neoplasms, 4 studies
- Colorectal Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.